Actively Recruiting
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
Led by Zabeen Mahuwala, MD · Updated on 2026-01-30
40
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the relationship between amylin, a hormone increased in people with Type-2 diabetes, and peripheral neuropathy symptoms in patients with this condition. The study explores whether the amount of amylin in the upper limbs correlates with the severity of nerve damage symptoms. This observational study aims to better understand how diabetes-related vascular damage affects nerve function and may identify biomarkers for disease severity. Participants will provide blood samples and skin biopsies from the forearm to measure amylin deposition in blood vessels and red blood cells. The study also includes nerve conduction velocity tests and sensory assessments of pain and temperature response in the upper extremities. These tests occur at the time of sample collection and follow-up sensory testing one week later. Throughout the study, participants undergo clinical sensory exams, nerve conduction velocity testing, and pain threshold evaluations using pressure, cold, and heat stimuli. Researchers will compare amylin levels to symptom severity and nerve function. The study collects data at single time points and includes follow-up sensory testing to provide preliminary insights for larger trials. Total participation involves initial testing and follow-up assessments one week later.
CONDITIONS
Brief Title
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subject has been diagnosed with Type-2 Diabetes.
- Subject shows mild-to-severe peripheral neuropathy, as determined by Nerve Conduction Velocity (NCV) tests.
- Adults aged 18 years or older.
You will not qualify if you...
- Subject has not been diagnosed with Type-2 Diabetes.
- Subject shows average, or above average performance on Nerve Conduction Velocity (NCV) tests.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 day
Participants undergo nerve conduction studies, blood sample collection, and skin punch biopsy to measure amylin levels and assess peripheral neuropathy severity.
1 visit (in-person)
Duration - 1 week after diagnostic evaluation
Participants undergo pressure pain threshold, cold pressor, and heat thermode tests to further assess neuropathy severity and its association with amylin levels.
1 visit (in-person)
Trial Site Locations
Total: 2 locations
1
UK Robert Straus Behavioral Science Laboratory
Lexington, Kentucky, United States, 40508
Active, Not Recruiting
2
University of Kentucky - Kentucky Neuroscience Institute
Lexington, Kentucky, United States, 40536
Actively Recruiting
Research Team
R
Rani Priyanka Vasireddy, MBBS, MHA
J
John T Slevin, M.D., M.B.A.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here